Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CUSP06 in platinum-refractory/resistant ovarian cancer and advanced solid tumors
NCT06234423Phase 1Recruiting
- Sponsor
- OnCusp Therapeutics
- Start
- Feb 2024
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of cusp06 in ovarian cancer and solid tumor (3 cohorts), sponsored by OnCusp Therapeutics. Primary endpoints: Safety and Tolerability of CUSP06 at 36 months, Recommended Dose for Expansion at 15 months and 1 more. Started Feb 2024; status: recruiting.
02
Drugs
cusp06
03
Conditions
ovarian cancersolid tumor
Beyond the preview
Go deeper on NCT06234423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06234423.